Wedge Capital Management L L P NC increased its stake in shares of CRH Medical Corp (NYSEAMERICAN:CRHM) by 25.7% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 118,903 shares of the company’s stock after acquiring an additional 24,347 shares during the quarter. Wedge Capital Management L L P NC’s holdings in CRH Medical were worth $316,000 at the end of the most recent quarter.
Other large investors also recently made changes to their positions in the company. Mackenzie Financial Corp acquired a new stake in CRH Medical during the 4th quarter worth $1,413,000. Morgan Stanley raised its stake in CRH Medical by 116.7% during the 3rd quarter. Morgan Stanley now owns 3,653,460 shares of the company’s stock worth $14,432,000 after acquiring an additional 1,967,537 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its stake in CRH Medical by 21.7% during the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 2,201,799 shares of the company’s stock worth $6,739,000 after acquiring an additional 392,900 shares in the last quarter. Acadian Asset Management LLC raised its stake in CRH Medical by 163.9% during the 4th quarter. Acadian Asset Management LLC now owns 234,320 shares of the company’s stock worth $716,000 after acquiring an additional 145,520 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its stake in CRH Medical by 38.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,486,400 shares of the company’s stock worth $5,871,000 after acquiring an additional 409,100 shares in the last quarter.
NYSEAMERICAN CRHM traded up $0.02 during trading on Friday, reaching $2.90. The company’s stock had a trading volume of 100 shares, compared to its average volume of 76,364. CRH Medical Corp has a twelve month low of $2.51 and a twelve month high of $4.50.
CRH Medical (NYSEAMERICAN:CRHM) last issued its quarterly earnings results on Wednesday, March 13th. The company reported $0.02 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.02. The firm had revenue of $32.02 million for the quarter, compared to analyst estimates of $31.40 million.
A number of research firms have commented on CRHM. Zacks Investment Research lowered shares of CRH Medical from a “buy” rating to a “hold” rating in a research note on Wednesday, March 20th. TheStreet lowered shares of CRH Medical from a “b-” rating to a “c+” rating in a research note on Friday, March 29th. Finally, Clarus Securities restated a “buy” rating on shares of CRH Medical in a research note on Wednesday, March 20th.
ILLEGAL ACTIVITY WARNING: This news story was originally posted by Stock Observer and is owned by of Stock Observer. If you are accessing this news story on another website, it was stolen and republished in violation of US and international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.thestockobserver.com/2019/05/17/crh-medical-corp-crhm-shares-bought-by-wedge-capital-management-l-l-p-nc.html.
CRH Medical Company Profile
CRH Medical Corporation provides various products and services to gastroenterologists in the United States and Canada. It offers CRH O'Regan system, a single use, disposable, and hemorrhoid banding technology for treating various grades of hemorrhoid. The company also offers anesthesia services for patients undergoing endoscopic procedures.
Further Reading: What is the LIBOR?
Want to see what other hedge funds are holding CRHM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CRH Medical Corp (NYSEAMERICAN:CRHM).
Receive News & Ratings for CRH Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRH Medical and related companies with MarketBeat.com's FREE daily email newsletter.